Imatib 400 mg tablets, containing Imatinib Mesylate, are a breakthrough in the treatment of Chronic Myeloid Leukemia (CML) and Gastrointestinal Stromal Tumors (GIST). As a targeted therapy, Imatib blocks abnormal proteins that cause cancer cells to grow and multiply, helping slow disease progression and improve patient survival. For many patients, it offers hope and better quality of life during cancer treatment.
For hospitals, clinics, and distributors, sourcing from a trusted Imatib 400 mg exporter ensures steady access to this life-saving medicine, making advanced cancer care more affordable and widely available.